Skip to main content
Premium Trial:

Request an Annual Quote

Dolomite to Collaborate on EU-funded Microfluidics Tech for Stem Cells

NEW YORK (GenomeWeb News) – UK-based microfluidics developer Dolomite said today that it will collaborate with the Danish firms Bioneer and OptoRobotix in a European Union-funded effort to develop a new stem cell handling device.

The consortium has received €820,100 ($1.1 million) from the EU's Eurostars program to fund the two-year project, which aims to develop a microfluidic tool that could be used in molecular biology, biotechnology, and pharmaceutical applications.

The OPTISORT platform will be a sorting and analysis tool that uses optical and droplet technologies for sorting fragile mammalian cells. It will enable stem cell biology and mammalian cell-based protein manufacturing, which the company said are both fast-developing fields.

OptoRobotix develops flow cytometers with cell sorting capabilities. Bioneer, a subsidiary of the Technical University of Denmark, provides access to tools to facilitate therapeutic, cellular, and molecular biology projects.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.